TY - JOUR T1 - Tumor Suppressor Immune Gene Therapy to Reverse Immunotherapy Resistance JF - medRxiv DO - 10.1101/2020.12.27.20248913 SP - 2020.12.27.20248913 AU - Sunil Chada AU - Dora Wiederhold AU - Kerstin B. Menander AU - Beatha Sellman AU - Max Talbott AU - John J. Nemunaitis AU - Hyo Min Ahn AU - Bo-Kyeong Jung AU - Chae-Ok Yun AU - Robert E. Sobol Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/02/2020.12.27.20248913.abstract N2 - Background While immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required overcome resistance to immunotherapies.Methods We investigated the effects of adenoviral p53 (Ad-p53) gene therapy in combination with immune checkpoint inhibitors and selective IL2 or IL15 CD122/132 agonists in the aggressive B16F10 tumor model resistant to immunotherapies. To assess potential mechanisms action, pre and post Ad-p53 treatment biopsies were evaluated for changes in gene expression profiles by Nanostring IO 360 assays.Results Substantial synergy of “triplet” Ad-p53 + CD122/132 + anti-PD-1 therapy resulted in potential curative effects associated with complete tumor remissions of both primary and contralateral tumors. Interestingly, contralateral tumors which were not injected with Ad-p53 showed robust abscopal effects resulting in statistically significant decreases in tumor size and increased survival (p<0.001). None of the monotherapies or doublet treatments induced complete tumor regressions. Ad-p53 treatment increased Type I Interferon, CD8+ T cell, immuno-proteosome antigen presentation and tumor inflammation gene signatures. Ad-p53 treatment also decreased immune suppressive TGF-beta, beta-catenin, macrophage, and endothelium gene signatures, which may contribute to enhanced immune checkpoint inhibitor (CPI) efficacy. Unexpectedly, a number of previously unidentified, strongly p53 down regulated genes associated with stromal pathways and IL10 expression identified novel anti-cancer therapeutic applications.Conclusions These results imply the ability of Ad-p53 to induce efficacious local and systemic anti-tumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complimentary immune mechanisms of action which support future clinical evaluation of triplet Ad-p53, CD122/132 agonist and immune checkpoint inhibitor combination treatment.Competing Interest StatementRES, SC, KBM, MT, BS and DW had consulting relationships with MultiVir Inc. The remaining authors have no conflicts of interest to declare.Clinical TrialNCT03544723Funding StatementThis work was supported by MultiVir Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by the ethics committee of the University of Toledo. The patients/participants provided their written informed consent to participate in this study. All mice-related experiments were performed under an approved protocol following the institutional guidelines established by the institutional animal care and use committee (IACUC) of Hanyang University. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the conclusions of this article are either incorporated in the manuscript, its supplemental section or available by the corresponding author upon reasonable request. ER -